Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00398047 · OUTCOME

Time to Progression to Acute Myeloid Leukemia (Blast ≥ 20%) or Death

Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes · Source last updated 2018-09-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Approximately 12 months

What was measured

Death during treatment or disease progression characterized by worsening of cytopenias, increase in the percentage of the blasts, reduction of hemoglobin concentration by at least 2 g/dl or transfusion dependence in the absence of another explanation, such as acute infection, gastrointestinal bleeding, hemolysis.

Analysis population: Because no patients completed therapy, no analysis was possible

Groups in this outcome

Azacitidine and Darbopoietin and G-CSF

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Azacitidine and Darbopoietin and G-CSF0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Death during treatment or disease progression characterized by worsening of cytopenias, increase in the percentage of the blasts, reduction of hemoglobin concentration by at least 2 g/dl or transfusion dependence in the absence of another explanation, such as acute infection, gastrointestinal bleeding, hemolysis.
groups
  1. id
    OG000
    title
    Azacitidine and Darbopoietin and G-CSF
population Description
Because no patients completed therapy, no analysis was possible
reporting Status
POSTED
time Frame
Approximately 12 months
title
Time to Progression to Acute Myeloid Leukemia (Blast ≥ 20%) or Death
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice